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The recognition between G protein and cognate receptor plays a key role in specific cellular responses to
environmental stimuli. Here we explore specificity in
receptor-G protein coupling by taking advantage of the
ability of the 5-hydroxytryptamine1B (5-HT1B) receptor
to discriminate between G protein heterotrimers containing Gai1 or Gat. Gi1 can interact with the 5-HT1B
receptor and stabilize a high affinity agonist binding
state of this receptor, but Gt cannot. A series of Gat/Gai1
chimeric proteins have been generated in Escherichia
coli, and their functional integrity has been reported
previously (Skiba, N. P., Bae, H., and Hamm, H. E. (1996)
J. Biol. Chem. 271, 413– 424). We have tested the functional coupling abilities of the Gat/Gai1 chimeras to 5HT1B receptors using high affinity agonist binding and
receptor-stimulated guanosine 5*-3-O-(thio)triphosphate (GTPgS) binding. In the presence of bg subunits,
amino acid residues 299 –318 of Gai1 increase agonist
binding to the 5-HT1B receptor and receptor stimulation
of GTPgS binding. Moreover, Gai1 containing only Gat
amino acid sequences from this region does not show
any coupling ability to 5-HT1B receptors. Our studies
suggest that the a4 helix and a4-b6 loop region of Gas
are an important region for specific recognition between receptors and Gi family members.

The heterotrimeric guanine nucleotide-binding regulatory
proteins (G proteins) mediate signaling from a large number of
diverse heptahelical cell surface receptors to a variety of intracellular effectors. These pathways control numerous essential
functions in all tissues and are ubiquitous throughout eukaryotes (1–3). A large body of work investigating the mechanisms underlying receptor-G protein interactions now exists.
The early view that signaling selectivity would manifest itself
on the basis of specific protein interactions allowing a receptor
to couple with a unique G protein to modulate a single effector
is no longer tenable with the accumulating evidence of a network of interactions that converge and diverge at multiple
levels. Even in the earliest receptor-G protein reconstitution
studies using phospholipid vesicles, it was clear that, while
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there were large differences in the efficiencies of coupling
among the major families of G proteins, receptors were capable
of activating multiple G proteins from distinct families (4, 5).
Elucidation of the crystal structures of a subunits in both
active (6, 7) and inactive conformations (8), an isolated bg
subunit (9) and the abg heterotrimer (10, 11), has begun to
define a mechanistic basis for data from mutagenesis, chimera,
and peptide studies defining functional domains on G protein
subunits (12–17). A variety of studies have implicated the C
terminus of a subunits in mediating receptor-G protein selectivity (13–15). Synthetic peptides from the C terminus of at
(amino acids 340 –350) have been shown to stabilize the active
conformation of metarhodopsin II (17) while alanine scanning
mutagenesis of the same region has identified four specific
residues crucial for at activation by rhodopsin (12). Similarly,
two C-terminal peptides from as (354 –372 and 384 –394), but
not the corresponding peptides from ai2, could evoke high affinity agonist binding to b-adrenergic receptors and block their
ability to activate as (16). Substitution of three to five C-terminal amino acids of aq with the corresponding residues from ai
allowed receptors that normally signal exclusively through ai
subunits to activate the chimeric a subunits and stimulate the
Gq effector, phospholipase C-b (PLC-b) (13). However, a similar
chimeric approach revealed that sequences in addition to the C
terminus were required for specificity of activation of a16 subunits by the C5a receptor (18). Other studies have also implicated a role for N-terminal sequences in receptor-G protein
coupling (17, 19). Thus it appears that the molecular determinants of receptor-G protein coupling vary somewhat among
specific families of receptors and G proteins. Studies presented
below have revealed a previously unappreciated region involved in receptor-G protein coupling that mediates the discrimination between ai and at subunits by 5hydroxytryptamine1B (5-HT1B)1 receptors. Furthermore, these
studies implicate a secondary role for an N-terminal a subunit
region, but not a C-terminal region, in stabilizing high affinity
agonist binding to 5-HT1B receptors as well as G protein activation (GTPgS binding).
EXPERIMENTAL PROCEDURES

Materials—GTP, GDP, GTPgS, AMP-PNP, deoxyribonucleotides,
and imidazole were purchased from Boehringer Mannheim. Restriction
enzymes, DNA modifying enzymes, and Taq DNA polymerase were
from Boehringer Mannheim and Pharmacia Biotech Inc. 5-HT was a
product of Sigma. [35S]GTPgS and [3H]5-HT were purchased from NEN
Life Science Products.

1
The abbreviations used are: 5-HT, 5-hydroxytryptamine; GTPgS,
guanosine 59-3-O-(thio)triphosphate; AMP-PNP, adenosine 59-(b,g imino)triphosphate; PCR, polymerase chain reaction; PMSF, phenylmethylsulfonyl fluoride; b-ME, b-mercaptoethanol; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.
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Construction of Gat/Gai1 Chimeric Genes—We used Escherichia coli
expression vectors pHis6Gai1 and pHis6Gat, which contain Gai1 or Gat
cDNAs, respectively, preceded by a nucleotide sequence encoding a
hexahistidine tag under the control of a T7 promoter (20). Chimeric
genes were constructed by insertion of unique restriction enzyme sites
into Gai1 or Gat cDNAs using PCR amplification with corresponding
oligonucleotide primers followed by replacement of Gai1 cDNA fragments with corresponding Gat cDNA fragments or vice versa. Insertion
of a NaeI site in the Gai1 cDNA corresponding to amino acid residues
298 –299 of Gai1, resulted in the replacement of Ala299 with Gly in Chi13
and Chi14. All other chimeras have only native amino acid residues
from the specific gene product as indicated.
Expression and Purification of Gat/Gai1 Chimeras—The chimeric Ga
subunits were expressed in E. coli BL21(DE3) cells and purified as
described previously (20). Briefly, cell pellets were resuspended in
Buffer A (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5 mM MgCl2, 50 mM
GDP, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), and 5 mM bmercaptoethanol (b-ME)) and were disrupted by ultrasonication. The
crude cell lysate was centrifuged at 100,000 3 g for 60 min, and the
supernatant was adjusted to 500 mM NaCl and 20 mM imidazole by
addition of 8 3 binding buffer (160 mM Tris-HCl, pH 8.0, 4 M NaCl, and
160 mM imidazole) before being loaded onto 5 ml of Ni21-nitrilotriacetic
acid-agarose resin column (His-Bond, Novagen) prepared according to
the manufacturer protocol. The column was washed with 10 volumes of
1 3 binding buffer followed by elution of the protein using Buffer I-100
(20 mM Tris-HCl, pH 8.0, 500 mM NaCl, and 100 mM imidazole). The
protein sample was dialyzed overnight against Buffer A in the presence
of 20% glycerol, PMSF, and b-ME and then further purified by high
performance liquid chromatography using anion exchange resin (Waters Protein-Pak QHR-15, Waters Chromatography) packed in an AP-1
column (Waters Chromatography). The samples were adjusted to 25 mM
GDP, 2 mM b-ME, 0.1 mM PMSF, and 40% glycerol and then stored at
280 °C. The purity of proteins was verified by SDS-polyacrylamide gel
electrophoresis. The protein concentrations were determined using the
Coomassie Blue method (21) with bovine serum albumin (Pierce) as the
standard.
Expression and Purification of G Proteins and 5-HT1B Receptors—
The expression in Sf 9 cells and purification of the recombinant G
protein a and bg subunits were performed as described previously (22,
23) except that the final chromatography step was performed on 15
micron Waters Protein-Pak QHR (Waters Chromatography). Dr. Eric
Parker (Bristol-Myers Squibb Pharmaceutical Research Institute,
Wallingford, CT) provided the 5-HT1B receptor baculovirus. Membranes
from Sf 9 cells infected with these viruses typically contained 2– 6 pmol
of receptor/mg of membrane protein. The native retinal a (Gat) and bg
subunits used for the GTPgS binding experiment were purified as
described previously (24).
Preparation of Sf 9 Membranes Containing Expressed Receptors—
Sf 9 cells were infected with recombinant baculovirus containing cDNA
for the 5-HT1B receptor, cultured, and harvested as described previously (22). To prepare membranes, harvested cells were thawed in 15
times their wet weight of ice-cold homogenization buffer (10 mM TrisHCl, pH 8.0, 25 mM NaCl, 10 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM PMSF, 20 mg/ml of benzamidine, and 2 mg/ml each of
aprotinin, leupeptin, and pepstatin A) and burst by N2 cavitation (600
p.s.i., 20 min). Cavitated cells were centrifuged at 500 3 g for 10 min at
4 °C to remove the unbroken nuclei and cell debris. The supernatant
from the low speed spin was centrifuged at 28,000 3 g for 30 min at
4 °C. The supernatant was discarded, and the pellets were resuspended
and pooled in 35 ml of buffer (5 mM NaHEPES, pH 7.5, 1 mM EDTA, and
the same protease inhibitors as used in the homogenization buffer). The
membranes were washed twice, resuspended in the same buffer (1–3
mg of protein/ml), aliquoted, snap frozen in liquid nitrogen, and stored
at 270 °C.
Reconstitution of Receptors with Exogenous G Proteins—Frozen
membranes were thawed, pelleted in a refrigerated microcentrifuge (10
min), and resuspended at 8 –10 mg/ml in a reconstitution buffer (5 mM
NaHEPES, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 500 nM
GDP, 0.04% CHAPS). G protein subunits were diluted in the same
buffer such that the desired amount of subunit was contained in 1–5 ml.
Typically, 1–2 ml of G protein subunits were added to 15– 40 ml of
membrane suspension, and then the mixture was incubated at 25 °C for
15 min and held on ice until the start of the binding assay. Just prior to
the start of the binding assay, the reconstitution mixture was diluted
10 –12-fold with binding assay buffer (50 mM Tris-HCl, pH 7.5, 5 mM
MgCl2, 0.5 mM EDTA) such that the desired amount of membranes were
contained in 50 ml.
[3H]5-Hydroxytryptamine Binding Assay—[3H]5-HT binding to

20 –50 mg of membrane protein was determined in binding assay buffer
(50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 0.5 mM EDTA) in the presence of
the desired components. Nonspecific binding was determined by addition of 10 mM 5-HT. Incubations were for 1.5 h in a room temperature
shaker and were terminated by filtration over Whatman GF/C filters
using a Brandel cell harvester. The filters were rinsed 3 times with 4 ml
of ice-cold buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 0.5 mM EDTA,
0.01% NaAzide), placed in 4.5 ml of CytoScint (ICN Pharmaceuticals,
Costa Mesa, CA), and analyzed for amount of retained radioactivity in
a scintillation counter. To characterize levels of expressed receptors in
membrane preparations, saturation binding isotherms were used. In
these studies, the concentration of [3H]5-HT ranged from 0.07 to 250 nM
in a final volume of 500 ml. For reconstitution of high affinity agonist
binding in affinity shift assays, a single concentration (0.4 –1.2 nM) of
[3H]5-HT was used in a final volume of 150 ml. Radioligand purity was
monitored by chromatography on a Zorbax ODS column (4.6 3 150 mm)
using 1% triethylamine acetate (pH 4):methanol (95:5) as the mobile
phase. Radioligand was repurified or replaced when the radiochemical
purity fell below 85%.
Fluorescence Assay—To measure the folded state of chimeric Ga
molecules, intrinsic fluorescence was measured with a Perkin-Elmer
Corp. LS5B spectrofluorometer at room temperature in buffer (50 mM
Tris-HCl, pH 8.0, 50 mM NaCl, 5 mM MgCl2). The AlF2
4 -dependent
conformational changes of activated Ga subunits were monitored by
intrinsic tryptophan fluorescence changes with excitation at 280 nm
and emission at 340 nm. The relative increase in fluorescence of 200 nM
Ga subunits was determined from absorbance readings before and after
addition of 10 mM NaF and 20 mM AlCl3.
5-HT Receptor-stimulated GTPgS Binding Assay—Prior to the assay,
the Sf 9 cell membranes expressing 5-HT1B receptors were incubated
with 1 mM AMP-PNP at 37 °C for 1 h. Membranes (90 mg of protein, 3.4
fmol of receptor/mg) were reconstituted with the indicated Ga subunits
and retinal bg subunits on ice in 70 ml of reaction buffer (25 mM Hepes,
pH 7.4, 5 mM MgCl2, 1 mM EDTA, 100 mM NaCl, 1 mM dithiothreitol) for
30 min. Following reconstitution, the suspended membranes were diluted by the addition of 200 ml of reaction buffer containing 150 nM GDP
and 60 nM GTPgS. The reaction was initiated by transferring 30 ml of
reaction buffer containing carrier-free [35S]GTPgS (;7 3 106 cpm) to
the diluted membranes, and the reaction tube was incubated at 25 °C in
a water bath. In these experiments, the following final concentrations
were used: 1 nM 5-HT1B receptor (90 mg of protein/reaction, 3.4 fmol of
receptor/mg), 40 nM Ga, and 40 nM retinal bg. For agonist activation, 1
mM 5-HT was included. Samples (20 ml) were withdrawn at various
times, and the reaction was terminated by passing through a Millipore
Multiscreen-HA 96-well filtration plate followed immediately by 6
washes with 200 ml of ice-cold wash buffer (20 mM Tris-HCl, pH 7.4, 100
mM NaCl, 25 mM MgCl2). The filters were presoaked by washing 2 times
with 200 ml of ice-cold washing buffer before adding samples. The filters
were dried and punched out using a Millipore Multiscreen Puncher, and
the amount of retained radioactivity was quantified in a liquid scintillation counter.
RESULTS

Selective Interaction of Gi Family Members with 5-HT1B Receptors—Previous work has demonstrated the ability of 5-HT1B
receptors to form a high affinity agonist binding state in the
presence of G protein heterotrimers containing ai/o but not at
subunits (25). Moreover, the discrimination was shown to be
entirely at the level of the at subunit as bovine brain or retinal
bg subunits were equally effective in formation of the high
affinity agonist binding state in the presence of ai/o subunits
(25). These observations made it possible to use recombinant
Gat/Gai1 chimeric proteins produced in E. coli to map the
regions of the Gai subunit responsible for differential coupling
with this receptor. These chimeric proteins are properly folded
and functional by a variety of criteria: they bind GDP, undergo
catalyzed GTP/GDP exchange in the presence of retinal bg
subunits and light activated rhodopsin, and take on the active,
GTP-bound conformation. The chimeric proteins and Gai1 contain a hexahistidine tag at the N terminus to facilitate purification using metal ion affinity chromatography. The ability of
chimeric proteins to bind GDP and undergo conformational
change upon binding to GTP was tested by determining if the
proteins undergo an AlF2
4 -dependent increase in tryptophan
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TABLE I
Affinity shift activity and Alf 23
4 -dependent tryptophan fluorescence change of Ga subunits with secondary structure
Numbers above the structures symbolizing chimeras indicate the junction points of Gat and Gai1 sequences and refer to amino acid positions in
Gat. Affinity shift activities refer to the -fold enhancement above buffer controls of high affinity [3H]5-HT binding in membranes expressing 5-HT1B
receptors reconstituted with G protein heterotrimers containing the indicated Ga subunits (see text and Fig. 3 for additional explanation). The
affinity shift activity data represent the mean 6 S.E. from the indicated number of experiments. *, activity of native Gat; **, activity of Gai1
expressed in E. coli.

a

Percent increase of tryptophan fluorescence in the presence of 10 mM NaF and 20 mM AlCl3 (see “Experimental Procedures” for detail).

fluorescence (20). This assay is based on the ability of AlF2
4,
which mimics the g-phosphate of GTP, to induce the active
conformation resulting in an increase in intrinsic fluorescence
of Trp207 in Gat (Trp211 in Gai1). Tryptophan fluorescence of all
chimeras and Gai1 used in this study increases 40 – 45% upon
the addition of AlF2
4 (Table I), which is consistent with our
previous results (20). The chimeric Gat/Gai1 proteins used are
shown schematically in Table I.
Fig. 1 compares the abilities of the indicated heterotrimers to
interact functionally with 5-HT1B receptors in an “affinityshift” assay. This assay takes advantage of the fact that the
majority of the receptors expressed in Sf 9 cells are in a low
affinity state for agonist and can be converted to a high affinity
state for agonist by the addition of appropriate exogenous G
protein heterotrimers (25). Agonist binding to reconstituted
membranes using a single, low concentration of agonist (near
the KD for the high affinity state and well below the KD for the
low affinity state) readily detects the formation of the high
affinity state as an enhanced level of binding. This assay has
been completely described for several receptors expressed in
Sf 9 cells (25, 26) and is based on earlier work with native
receptors (27, 28). In the absence of any added G protein, Sf 9
cell membranes expressing 5-HT1B receptors exhibit a small
amount of high affinity agonist binding, which is decreased by
GTPgS. This suggests that endogenous G proteins present in
Sf 9 cells couple a small number of the expressed receptors. Fig.
1 shows that bacterially expressed, non-myristoylated ai1 was
able to support high affinity agonist binding although the apparent affinity for agonist is somewhat less than with acylated
ai1 expressed in Sf 9 cells. Although the G proteins were present in saturating amounts (data not shown), ;14% less [3H]5HT was bound in the presence of Gai1 expressed in E. coli
compared with Gai1 expressed in Sf 9 cells. Fig. 1 also shows
that GTPgS eliminates the high affinity agonist binding stabilized by either Gai1, consistent with the interpretation that the
added G proteins are coupling the expressed receptor in the

accepted fashion. Retinal Gt has no effect on agonist binding.
Importantly, as shown in Fig. 1, Chi6 is also unable to functionally couple with the 5-HT1B receptor. This chimera (Chi6)
differs from native at at just 26 positions between amino acids
215–295 of at (see Table I) and closely resembles native at in its
interactions with cGMP phosphodiesterase-g (the transducin
effector) and rhodopsin (the visual receptor that activates
transducin), as well as, in its intrinsic guanine nucleotide exchange properties (20). Additional experiments, in which Chi6
has been reconstituted at a concentration of 3 mM in a 310-fold
molar excess over receptor, have given no indication that Chi6
can functionally couple with 5-HT1B receptors (data not
shown).
The 5-HT1B receptor also distinguishes between Gi and Gt in
terms of G protein activation. We used a GTPgS binding assay
to quantitate agonist-dependent receptor-catalyzed GTP/GDP
exchange. The data in Fig. 2 show that Gai1 undergoes GTP/
GDP exchange by agonist-activated 5-HT1B receptor in the
presence of retinal bg. In contrast, Chi6, the Gat-like chimera,
does not exchange GDP for GTP in the presence of agonistactivated receptors. The relatively high basal rate of GTP/GDP
exchange on Gai1 seen in this assay is similar to previously
reported data (20, 29). Based on the high affinity agonist binding and GTP/GDP exchange data, we decided to explore the
molecular basis of this discrimination between Gai1 and Gat by
5-HT1B receptors.
Affinity Shift Activity of Different Gat/Gai1 Chimeras with
5-HT1B Receptors—With respect to the ability of specific G
proteins to induce the high affinity agonist binding state of
heptahelical receptors, previous work with both 5-HT1A and
5-HT1B receptors has shown that differences among various
Gai/o subunits are largely in the affinity of the receptor for
agonist rather than in the affinity of the receptor for the G
protein (25). Thus as increasing amounts of G proteins were
added to Sf 9 cell membranes containing expressed receptors,
maximal levels of high affinity agonist binding (as measured in
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FIG. 1. [3H]5-HT binding in membranes from Sf 9 cells reconstituted
with G protein subunits. Membranes
(20 mg of protein/filter, 3.4 fmol of receptor/mg) from Sf 9 cells expressing 5-HT1B
receptors were reconstituted with buffer
(Control) or the indicated Ga subunits
with an excess of bg subunits and used in
a [3H]5-HT binding assay as described
under “Experimental Procedures.” The
concentration of [3H]5-HT used was 0.5
nM, and the Ga subunits were present in
100-fold molar excess (45 nM final concentration) over receptors. Bars represent
specific binding as the mean 6 S.D. of
triplicate determinations from a representative experiment.

FIG. 2. 5-HT1B receptor catalyzed GTP/GDP exchange on Gt
versus Gi1. Membranes expressing 5-HT1B receptor were reconstituted
with either Gai1 (panel A) or Chi 6 (panel B) and bg subunits. Squares
indicate GTPgS binding in the presence of 1 mM 5-HT (added at the 8.5
min point), and triangles indicate the binding in the absence of agonist.
Final concentrations used were: 40 nM Gabg subunits, 1 nM 5-HT1B
receptors (6 mg of protein/filter, 3.4 fmol of receptor/mg), 40 nM
[35S]GTPgS, and 100 nM GDP. Aliquots were withdrawn at the indicated times, filtered, and counted. Data shown are the mean 6 S.E. of
four independent experiments.

the presence of a single low concentration of agonist) were
achieved. The maximal levels achieved differed depending on
the identity of the Gai/o subunit, whereas the amount of the
Gai/o subunits required to produce the maximal level of binding
did not differ significantly for a given receptor (25). Typically,
maximal levels of high affinity agonist binding have been
achieved with a 5–20-fold molar excess of G protein over receptor (25, 26). In the present study, the actual concentration of
agonist varied slightly in separate experiments, and small variations in agonist concentration at the low concentrations used
in affinity shift assays result in significant differences in the
absolute levels of binding observed. Therefore, it was necessary
to define an affinity shift activity to compare the abilities of the

Gat/Gai1 chimeras to undergo functional interactions with 5HT1B receptors. Affinity shift activity has been defined as the
-fold enhancement above buffer controls of high affinity [3H]5HT binding in membranes expressing 5-HT1B receptors reconstituted with G protein heterotrimers in 40 –100-fold molar
excess over receptors. Subunits with no ability to produce a
high affinity agonist binding state in 5-HT1B receptors would
have an affinity shift activity of 1, whereas those subunits with
similar abilities as fully myristoylated Gai/o subunits would
have affinity shift activities between 3 and 4. Fig. 3 summarizes the affinity shift activities of the Gat/Gai1 chimeras depicted in Table I. These determinations have been made in
3–13 independent experiments using four separate membrane
preparations where 5-HT1B receptors were expressed between
3–10 pmol/mg membrane protein and exogenous G protein
concentrations ranged from 0.3–1.0 mM during reconstitution.
The concentration of [3H]5-HT used in the binding assays was
0.6 –1.2 nM in all experiments. Within each experiment, the
concentrations of G proteins and receptors were identical for all
chimeras being tested, and each experiment included Ga subunits with minimal (native Gat or Chi6) and maximal (Gai1
expressed in E. coli or Sf 9 cells) affinity shift activities.
Based upon the observation that Chi6, the at-like chimera,
cannot couple to the 5-HT1B receptor, we constructed Chi2 and
Chi21 to determine whether the N-terminal or C-terminal region of Gai1 underlies functional coupling. Fig. 3 shows that
Chi2 still has no ability to induce high-affinity agonist binding,
whereas Chi21 is nearly as effective as Gai1 (2.12 6 0.13-fold
and 2.96 6 0.16-fold increase, respectively). From this, we
conclude that functional coupling is contributed by residues in
the C-terminal 55 residues of Gai1. Examination of the amino
acid sequences of Gai1 and Gat show that they are highly
similar in sequence from b-sheet 6 to the C terminus. Thus we
constructed Chi14, which is identical to Chi6 except for the
replacement of residues 295–314 of Gat with the corresponding
residues of Gai1 (residues 299 –318). This chimera supports
high affinity agonist binding to the same degree as Chi21. To
examine how critical these residues are for receptor interaction, Chi3 was constructed, which changed just these residues
back to the Gat sequence in the context of Gai1. Chi3, even
when reconstituted at a concentration of 1.7 mM in a 175-fold
molar excess over receptor, has no ability to stabilize high
affinity agonist binding to 5-HT1B receptors (data not shown),
proving that this region contains a key determinant of receptor
coupling.
Although several lines of experiments suggest that the C-
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FIG. 3. Affinity shift activity of various Gat/Gai1 chimeras with
5-HT1B receptors. Affinity shift activities refer to the -fold enhancement above buffer controls of high affinity [3H]5-HT binding to 5-HT1B
receptors reconstituted with G protein heterotrimers containing the
indicated a subunits (see “Results” for further explanation). Data represent the mean 6 S.E. from three to thirteen independent determinations using four separate membrane preparations where 5-HT1B receptors were expressed between 3–10 pmol/mg membrane protein, and
exogenous G protein concentrations ranged from 0.3 to 1.0 mM during
reconstitution. The concentration of [3H]5-HT was between 0.6 and 1.2
nM in all experiments. Gat represents the activity of native transducin,
and Gai1 represents the activity of ai1 expressed in E. coli.

terminal regions (a5, and C-terminal tail) of Ga subunits are
critical for receptor coupling and selective G protein-receptor
interaction (12–17), examination of the role of these regions by
comparing Chi14 with Chi21, which includes an additional
C-terminal 35 amino acid residues of Gai1 not present in Chi14,
shows that Chi14 and Chi21 have similar affinity shift activity.
This may be because there are few amino acid differences
between Gai1 and Gat in this region. To understand why high
affinity agonist binding with Chi14 and Chi21 is less than with
Gai1 (Fig. 3), Chi13 was constructed containing the key residues 299 –318 of Gai1, as well as the N-terminal half of Gai1.
Chi13 enhanced high affinity agonist binding to the same extent as Gai1 and to a significantly greater extent than either
Chi14 or Chi21. Comparing the affinity shift activity of Chi14
and Chi13 allows the conclusion that important determinants
of receptor interaction are also present in the N-terminal half
of Gai1, but they are dependent on the presence of the Cterminal determinants (amino acids 299 –318 of Gai1). The
nature of this role of the Ga N-terminal region in receptor
interaction is not based on the N-terminal acyl modifications
since none of the bacterially expressed proteins are acylated.
To demonstrate that receptor coupling with Chi14 and Gai1
resulted in different agonist affinities rather than different
affinities between receptor and G protein, we compared the
concentration dependence of the Ga subunits in an affinity
shift assay. The data in Fig. 4 show that, while the EC50 (3.8 6
1.2 versus 6.4 6 1.7 nM for Chi14 and Gai1, respectively) for
formation of high affinity agonist binding sites by Chi14 and
Gai1 are not significantly different, the ;38% difference in the
amount of agonist binding is highly significant (p , 0.0001).
Although smaller in magnitude, significant differences in levels of high affinity agonist binding among Gai/o subunits have
been seen with both 5-HT1A and 5-HT1B receptors (25).
Table I summarizes the affinity shift activity of Gat, Gai1,
and chimeric Ga subunits on 5-HT1B receptors in the presence
of bg subunits. We can categorize three groups of Gat/Gai1
chimeric proteins according to differences in their abilities to
enhance high affinity agonist binding. The first group of chimeric proteins (Chi6, Chi2, Chi3, and Chi15) do not produce
any significant increase in high affinity agonist binding. All
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FIG. 4. Concentration dependence of ai1 and Chi14 in an affinity shift assay with 5-HT1B receptors. Sf 9 cell membranes (17.5 mg
of protein/filter, 4.8 fmol of receptor/mg) expressing 5-HT1B receptors
were reconstituted with the indicated concentrations of Gai1 or Chi14
with an excess of bg subunits. The highest concentration of a subunits
represents an estimated 75-fold molar excess over expressed receptors.
The concentration of [3H]5-HT used was 1.2 nM. Data points represent
specific binding expressed as the mean 6 S.D. of triplicate determinations from a representative experiment. The solid lines indicate the best
fit to the data of a single-site interaction between receptor and G
protein governed by the law of mass action.

chimeras in the first group contain the 295–314 amino acid
sequence from Gat (a4 helix and a4/b6 loop). The second group,
including Chi14 and Chi21, have an intermediate effect on high
affinity agonist binding compared with Gai1. These two chimeras contain amino acid residues 299 –318 of Gai1 sequence and
the N-terminal 215 amino acid residues from Gat. Amazingly,
replacing only the 295–314 region of Chi6 with the homologous
region from Gai1 (Chi14) recovers ;82% of the affinity shift
activity of Gai1. The third group, which includes Chi13 and
Gai1, exhibits the maximum affinity shift activity. Thus, the
N-terminal domain of Gai1 may act synergistically with the
299 –318 region of Gai1 to enhance high affinity agonist binding
to the 5-HT1B receptor. However, the N-terminal region is not
sufficient for functional coupling with 5-HT1B receptors since
no significant effects on high affinity agonist binding were
observed with the chimeras containing the Gai1 N terminus
without the 299 –318 region of Gai1 (Chi2 and Chi3).
Agonist-Stimulated GTP/GDP Exchange of Gat/Gai1 Chimeras—We next determined the relationship between high
affinity agonist binding to the 5-HT1B receptor and G protein
activation by the receptor. The data in Fig. 5 demonstrate that
Chi14 undergoes significant 5-HT1B receptor-stimulated GTP/
GDP exchange (from 0.01 6 0.71 to 23.99 6 2.73 pmol/mgzmin)
although only half as well as Gai1 (46.46 6 4.37 pmol/mgzmin).
Chi13 becomes activated as well as Gai1 by the receptor; however, Chi2 does not show any significant agonist-stimulated
guanine nucleotide exchange, suggesting that the N-terminal
domain of Gai1 has only a minor and conditional effect on the
receptor-stimulated G protein activation. In addition, the absence of agonist-stimulated GTP/GDP exchange on Chi3 clearly
proves the importance of amino acid residues 299 –318 of Gai1
on receptor stimulated G protein activation. Thus, the regions
of the Gai subunit important for stabilizing the high affinity
agonist binding state of the 5-HT1B receptor are also important
for receptor catalyzed GTP/GDP exchange.
DISCUSSION

In this study, we found a new region of Gai important for
specific interaction with 5-HT1B receptors using in vitro recon-
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stitution of Sf 9 cell membranes containing overexpressed
5-HT1B receptors with chimeric Ga subunits. We provide
strong evidence that the a4 helix and a4-b6 loop are critical for
specific 5-HT1B receptor-Gi1 interaction and are required for G
protein activation by the receptor. Amino acid sequence alignment shows that Gai1, Gai2, and Gai3 are highly conserved in
the a4 helix and a4-b6 loop region while Gat has 9 residues
which differ from Gai1 (Fig. 6). In addition, the amino acid
sequence of this region is diverse among the different families
of Ga subunits, supporting the idea that the a4 helix and a4-b6
loop of Ga is another binding domain necessary for selective
interaction with appropriate heptahelical receptors. This domain has previously been implicated in receptor interaction.
Mazzoni et al. reported that Arg310 of Gat is completely protected from tryptic proteolysis in the presence of light-activated
rhodopsin while it is a major site of tryptic cleavage of free Gat
or heterotrimeric Gt (30), suggesting that the a4-b6 loop may
be a point of receptor contact. In addition, a recent site-directed
mutagenesis study demonstrated that four single alanine substituted mutants in the a4-b6 loop region of Gat (Arg309,
Asp311, Val312, and Lys313) are each defective in their ability to
interact with light-activated rhodopsin (12).
Interestingly, the a4 helix and a4-b6 loop of the Ga subunit
was originally identified as an effector coupling site. Synthetic
peptides from amino acids 293–314 of Gat activate cGMP-

FIG. 5. 5-HT1B receptor catalyzed GTP/GDP exchange on various Gat/Gai1 chimeras. Membranes expressing 5-HT1B receptors
were reconstituted with the indicated chimeras and bg subunits.
Curves depict the difference between the rates of GTPgS binding in the
presence and absence of 1 mM 5-HT. Final concentrations used were: 40
nM G protein subunits, 1 nM 5-HT1B (6 mg of protein/filter, 3.4 fmol of
receptor/mg), 40 nM [35S]GTPgS, and 100 nM GDP. Data shown are the
mean 6 S.E. of four independent experiments. The inset depicts the rate
of agonist-stimulated GTPgS binding and -fold increase over basal
based on this figure.

phosphodiesterase (PDE) (31), and PDEg can be cross-linked to
this loop (32, 33). Our data thus suggest that the receptor
binding domain is adjacent to or partially overlaps the effector
interacting domain in Ga subunits. In support of this, Artemyev (34) recently found that cGMP phosphodiesterase g subunit, an effector of Gat, can prevent the interaction between Gt
and light-activated rhodopsin.
This study also implicates another region of Gai1 important
for 5-HT1B receptor interaction. The N-terminal 210 amino
acids of Gai1 imparted increased high affinity agonist binding
to the 5-HT1B receptor. Some part of the N-terminal half of Gai1
(not further specified) acts synergistically with the a4 helix and
a4-b6 loop to enhance high affinity agonist binding to 5-HT1B
receptors. However, the N-terminal region is not sufficient on
its own for functional coupling with 5-HT1B receptors since no
significant effect on high affinity agonist binding was observed
with chimeras containing only the N-terminal half of Gai1.
It has been postulated that the GDP bound form of the G
protein interacts with agonist-activated receptors and results
in the release of GDP from the Ga subunit. This guanine
nucleotide-free G protein is able to tightly bind agonist-bound
receptors, and this complex can be released from the receptor
by GDP or GTP (41, 42), suggesting that the conformation of
“empty-state” Ga subunit is different from the previously crystallized GDP- and GTPgS-bound forms of Ga subunits (6, 8).
Thus, any defect in receptor-catalyzed GDP release from the
Ga subunit would result in a failure to form the ternary complex of agonist, receptor, and G protein. This hypothesis is
supported by our finding that all chimeras which lacked the
ability to undergo receptor-catalyzed GTP/GDP exchange also
failed to induce high affinity agonist binding by the receptor
(Table I and Fig. 3). As the rate-limiting step in G protein
activation is release of the GDP from the Ga subunit, GTP/GDP
exchange should be a direct reflection of GDP release. Therefore, we speculate that the a4 helix and a4-b6 loop of Ga is
necessary for GDP release following binding to an activated
receptor, and subsequently results in the empty state of Ga
that can further stabilize the ligand bound receptor.
How does this finding relate to the well-established role of
the G protein C terminus in receptor interactions? The Cterminal region clearly plays a central role in coupling G proteins to receptors (12–17). A body of evidence also demonstrates
that it is important in class-specific selectivity of receptor-G
protein interactions; changing the last few amino acids at the C
terminus can recruit, for example, Gi-coupled receptors to activate Gq (13). In the case of receptor selectivity within a class
of G proteins, in this study the 5-HT1B receptor interaction
with Gi1, the amino acid sequences of the C-terminal 35 amino
acids of Gai1 are so highly similar to Gat that it is unlikely that
selectivity is imparted by this region. We show, in fact, that
switching the C-terminal 35 amino acids from Gat to Gai1 has
no effect on coupling with the 5-HT1B receptor. Other regions of
G proteins may also be important for receptor interaction. The
N-terminal region has been implicated in receptor interaction
(17, 19), and in the present study, the N-terminal half of Gai1
has a secondary role in 5-HT1B receptor coupling. In the case of

FIG. 6. Alignment of a4-a4/b6 region and the C terminus of Gai family. Numbers above the sequences refer to amino acid positions in the
context of Gat. Boldface letters represent identical amino acid residues among Gai1 subunits. bov., bovine; hum., human; cavpo., guinea pig.

5-HT1B Receptor Binding Sites on Inhibitory G Protein
Ga16 and the C5a receptor, a chimeric protein approach revealed that yet another region, including the a2 helix and the
a2/b4 loop, is involved in receptor-mediated G protein activation (18). In addition to the a subunit, the C-terminal region of
the g subunit of G proteins is also important for receptor
coupling and specificity (35–38).
Thus multiple regions of G proteins make up interfaces for
interactions with receptors. The region we have defined is
positioned in the three-dimensional structure to potentially
affect GDP binding affinities. This region is connected by a
short b sheet, b6, to nucleotide binding residues TCAT that
engage the guanine ring (6, 8). Mutations in this region dramatically decreased affinity for GDP (12, 39, 40). This conserved TCAT is in fact located between the a4-a4/b6 loop and
the a5-C terminus, which were previously identified as receptor binding domains (12–17). Consistent with the structural
and biochemical findings, the selective interaction of these
regions (a4-a4/b6 loop and a5-C terminus) with an activated
receptor may induce a conformational change in the TCAT
motif and catalyze GDP release from the nucleotide binding
pocket in the Ga subunits.
In this study, we clearly show that proper fit between the
5-HT1B receptor and the a4-a4/b6 loop region is required for
GDP release from Gi1. It also appears that different receptors
have different structural requirements for G protein coupling.
Some receptors, such as rhodopsin, do not distinguish between
Gi family members. Other Gi coupled receptors are able to
distinguish to different degrees among Gi family members (25,
43– 47). The 5-HT1B receptor is an example of such selectivity
as this receptor fails to couple with transducin or Chi6, the
transducin-like chimera. The degree of contact between receptor and the a4-a4/b6 loop region of Ga subunits might vary
depending on the three-dimensional surface of each receptor
type. Considering the high degree of structural homology
among G proteins, we speculate that the general mechanism of
G protein-receptor coupling will be conserved among different
classes of G proteins and receptors. Future studies will determine in more detail regions on Ga important for selective
coupling with other receptors.
In summary, we have identified two distinct regions in Gai1
important in specific G protein 5-HT1B receptor interaction: 1)
299 –318 Gai1 (a4 and a4-b6 loop), and 2) 1–219 Gai1. The
region of 299 –318 Gai1 is necessary for both high affinity
agonist binding and agonist-stimulated G protein activation.
The other region, 1–219 Gai1 has a minor and conditional effect
on the apparent affinity state of the receptor. Data on the
regions of Gai involved in the high affinity agonist binding and
in receptor-mediated GTP/GDP exchange correlated well.
These observations suggest a close relationship between the
mechanism of G protein activation by the receptor and the
ability of G proteins to stabilize the high affinity agonist binding state of receptors. An important goal is to define the nature
of this interaction, the mechanisms by which receptors catalyze
GDP release, and the roles of the various contact regions in
determining selectivity of receptor G protein interaction.
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